3-37047562-G-C
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BP6
The NM_000249.4(MLH1):c.1775G>C(p.Ser592Thr) variant causes a missense change. The variant allele was found at a frequency of 0.00000682 in 1,614,028 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000249.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152166Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251258Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135772
GnomAD4 exome AF: 0.00000547 AC: 8AN: 1461862Hom.: 0 Cov.: 31 AF XY: 0.00000413 AC XY: 3AN XY: 727234
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152166Hom.: 0 Cov.: 31 AF XY: 0.0000269 AC XY: 2AN XY: 74342
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:3
- -
The p.S592T variant (also known as c.1775G>C), located in coding exon 16 of the MLH1 gene, results from a G to C substitution at nucleotide position 1775. The serine at codon 592 is replaced by threonine, an amino acid with similar properties. This alteration was identified in an individual with pancreatic cancer who also had a CDKN2A gene mutation (Yang XR et al. Hum. Genet. 2016 Nov;135:1241-1249). This alteration was seen in 1/150 unselected patients with recurrent or metastatic prostate cancer (Isaacsson Velho P et al. Prostate. 2018 04;78:401-407). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
This missense variant replaces serine with threonine at codon 592 of the MLH1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been observed in an individual affected with pancreatic cancer, who also carried an unspecified CDKN2A variant (PMID: 27449771), as well as in an individual affected with prostate cancer (PMID: 29368341). This variant has been identified in 3/251258 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Colorectal cancer, hereditary nonpolyposis, type 2 Uncertain:2Benign:1
- -
- -
This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 27363726]. -
Lynch syndrome Uncertain:2
- -
This missense variant replaces serine with threonine at codon 592 of the MLH1 protein. Computational prediction tool is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has been observed in an individual affected with pancreatic cancer who also has an unspecified CDKN2A variant (PMID: 27449771). This variant has been identified in 3/251258 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
not provided Uncertain:2
Observed in an individual with prostate cancer, in an individual with pancreatic cancer and a pathogenic CDKN2A variant, as well as in a patient with Li-Fraumeni syndrome and a pathogenic variant in TP53 (PMID: 27449771, 29368341, 37840845); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; In silico analysis suggests this variant may impact gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; This variant is associated with the following publications: (PMID: 30113427, 29368341, 27449771, 12799449, 20533529, 22753075, 37840845) -
MLH1: PM2, PS4:Moderate, BP4 -
not specified Uncertain:1
- -
Muir-Torré syndrome;C1333991:Colorectal cancer, hereditary nonpolyposis, type 2;C5399763:Mismatch repair cancer syndrome 1 Uncertain:1
- -
MLH1-related disorder Uncertain:1
The MLH1 c.1775G>C variant is predicted to result in the amino acid substitution p.Ser592Thr. This variant has been reported in an individual with pancreatic cancer and an individual with prostate cancer (Table S4, Yang et al. 2016, PubMed ID: 27449771; Table S1, Isaacsson Velho et al. 2018. PubMed ID: 29368341). This variant is reported in 3 of ~251,000 alleles in gnomAD (http://gnomad.broadinstitute.org/variant/3-37089053-G-C). It is interpreted as uncertain significance in ClinVar (https://preview.ncbi.nlm.nih.gov/clinvar/variation/142658/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at